## Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype.

3

Antoine Fayand<sup>1,2,\*</sup> MD, Margaux Cescato<sup>2,\*</sup> M.Sc, Laurent Le Corre<sup>2</sup> Ph.D, Alexandre 4 Terré<sup>1,3</sup> MD, Margaux Wacheux<sup>2</sup> M.Sc, Yixiang YJ Zhu<sup>2</sup> M.Sc, Armelle Melet<sup>2</sup> Ph.D, Thomas 5 RJ Moreau<sup>2,4</sup> M.Sc, Bahram Bodaghi<sup>5</sup> MD, Fabrice Bonnet<sup>6</sup> MD, Didier Bronnimann<sup>6</sup> MD, 6 Laurence Cuisset<sup>7</sup> MD, Raquel Faria<sup>8</sup> MD, Gilles Grateau<sup>1</sup> MD, Ph.D, Pascal Pillet<sup>9</sup> MD, 7 Catharina M Mulders-Manders<sup>10</sup> MD, Benedicte Neven<sup>11</sup> MD, Ph.D, Pierre Quartier<sup>11,12</sup> MD, 8 Ph.D, Olivier Richer<sup>9</sup> MD, Léa Savey<sup>1</sup> MD, Marie-Elise Truchetet<sup>13</sup> MD, Bénédicte F Py <sup>14</sup> 9 Ph.D, Guilaine Boursier<sup>15</sup> MD, Ph.D, Jean-Philippe Herbeuval<sup>2</sup> Ph.D, Sophie Georgin-Lavialle 10 <sup>1,&, †</sup> MD, Ph.D, Mathieu P Rodero<sup>2,& †</sup> Ph.D. 11

- 12
- <sup>1</sup> Sorbonne Université, department of internal medicine, National reference center for
   autoinflammatory diseases and AA amyloidosis, Tenon Hospital, APHP, Paris, France.
- <sup>2</sup> Université Paris Cité, CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et
   Toxicologiques, F-75006 Paris, France
- <sup>3</sup> Université Paris Cité, Inserm, Institut Imagine, Laboratoire Mécanismes cellulaires et moléculaires des désordres hématologiques et implications thérapeutiques, F-75015 Paris, France
- <sup>4</sup> Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.

<sup>5</sup> Sorbonne Université, department of Ophthalmology, IHU FOReSIGHT, Pitié-Salpêtrière

- 22 Hospital, APHP, Paris, France
- <sup>6</sup> CHU de Bordeaux, Hôpital Saint-André, Service de Médecine Interne et Maladies
   Infectieuses, Bordeaux, France
- <sup>7</sup> Université de Paris Cité, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris,
   France
- <sup>8</sup> Unidade de Imunologia Clínica Centro Hospitalar Universitário do Porto; UMIB Unit for
- 28 Multidisciplinary Research in Biomedicine, ICBAS School of Medicine and Biomedical

29 Sciences, University of Porto; ITR - Laboratory for Integrative and Translational Research in

- 30 Population Health, Porto, Portugal.
- <sup>9</sup> Service de pédiatrie et rhumatologie pédiatrique, Hôpital Pellegrin-enfants, Bordeaux
- <sup>10</sup> Department of Internal Medicine, Radboud expertise center for immunodeficiency and
- autoinflammation, Radboud University Medical Center, Nijmegen, The Netherlands.
- <sup>11</sup> Université de Paris Cité, Pediatric Immunology-Hematology and Rheumatology Unit,
- 35 Necker hospital, Paris, France.
- $^{12}$  RAISE reference centre for rare diseases

- <sup>13</sup> Department of Rheumatology, Hopital Pellegrin and UMR5164 ImmunoConcept, Bordeaux
   <sup>13</sup> University, Bordeaux University Hospital, Bordeaux, France.
- <sup>14</sup> CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,
- 40 Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
- 41 <sup>15</sup> Laboratoire de Génétique des Maladies rares et autoinflammatoires, Service de Génétique
- 42 moléculaire et cytogénomique, National reference center for autoinflammatory diseases and
- 43 AA amyloidosis, CHU Montpellier, Univ Montpellier, Montpellier, France
- 44
- 45 \* Contributed equally
- 46 & Codirected the study

47

- <sup>†</sup> Corresponding authors: Mathieu Rodero, UMR8601, 45 rue des St Pères 75006 Paris.
  <u>mathieu.rodero@u-paris.fr</u> and Sophie Georgin-Lavialle: Sorbonne Université, APHP, Tenon
  hospital, Department of Internal Medicine, National reference center for autoinflammatory
  diseases and inflammatory amyloidosis (CEREMAIA), Paris, France. sophie.georginlavialle@aphp.fr
- 53

#### 54 **Conflict of interest**

- 55 All the authors declare that they have no relevant conflicts of interest.
- 56
- 57

#### 58 Abstract

- 59
- Background: Cryopyrin-associated periodic syndrome (CAPS) is associated with *NLRP3* pathogenic variants, mostly located in the NACHT domain. Cold induced urticarial rash is one of the main clinical features. We however identified a series of 14 patients with pathogenic variants of the Y861 residue (p.Tyr861) of the LRR domain of NLRP3 and minimal prevalence of cold-induced urticarial rash.
- Objective: We aimed to address a possible genotype / phenotype correlation for CAPS
   patients and to investigate at the cellular levels the impact of the Y861C substitution
   (p.Tyr861Cys) on NLRP3 activation.
- Methods: Clinical features of 14 CAPS patients with heterozygous substitution at position 861 in the LRR domain of NLRP3 were compared to clinical features of 48 CAPS patients with pathogenic variants outside the LRR domain of NLRP3. IL-1β secretion by PBMCs and purified monocytes from patients and healthy donors was evaluated following LPS and MSU stimulation.
- Results: Patients with substitution at position 861 of NLRP3 demonstrated a higher
   prevalence of sensorineural hearing loss while being less prone to skin urticarial. In
   contrast to classical CAPS patients, cells from patients with a pathogenic variant at
   position 861 required an activation signal to secrete IL-1β but produced more IL-1β
   during the early and late phase of secretion than cells from healthy donors.
- Conclusion: Pathogenic variants of Y861 of NLRP3 drive a boost-dependent over secretion of IL-1β associated with an atypical CAPS phenotype.
- 80

### 81 Clinical Implications

- 82 *NLRP3* pathogenic variants should be considered as a possible cause of early onset hearing loss
- 83 in patients with elevated inflammatory biomarkers, even in the absence of skin urticarial rashes.
- 84

### 85 Capsule Summary

Pathogenic variants of the residue 861 of NLRP3 drive an atypical CAPS phenotype associated

87 with increased prevalence of hearing loss but less frequent skin urticaria compared to typical

- 88 CAPS.
- 89

#### 90 Key Words

- 91 NLRP3, CAPS, inflammasome, LRR domain, Interleukin-1, hear loss, deafness, urticaria
- 92
- 93
- 94
- 95

#### 96 Abbreviations

- 97 ASC: Apoptosis-associated speck-like protein containing a CARD domain
- 98 ATP: adenosine triphosphate
- 99 CAPS: cryopyrin-associated periodic syndrome
- 100 CD14: Cluster of differentiation 14
- 101 CRP: C-reactive protein
- 102 cryoEM: cryogenic electron microscopy
- 103 ELISA: enzyme-linked immunosorbent assay
- 104 FMF: Familial Mediterranean fever
- 105 HC: healthy control
- 106 LPS: lipopolysaccharide
- 107 MD: Molecular Dynamics
- 108 NACHT: NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC class 2 transcription
- activator), HET-E (incompatibility locus protein from Podospora anserina), TP1 (telomerase-associated protein)
- 111 NEK7: NIMA Related Kinase 7
- 112 NLRP3: NOD-like receptor family, pyrin domain containing 3
- 113 PBMC: Peripheral blood mononuclear cell
- 114 PRR: Pattern recognition receptors
- 115 RPMI: Roswell Park Memorial Institute medium
- 116 SEM: standard error of the mean
- 117 SD: standard deviation
- 118 TSM1: target of methylation-induced silencing
- 119 LRR: Leucine-Rich Repeat
- 120 IL-1 $\beta$ : interleukine 1 beta
- 121 IL-18: interleukine 18
- 122 MSU: monosodium urate crystals
- 123 WT: Wild-Type
- 124
- 125

#### 126 Introduction:

NOD-like receptor family, pyrin domain containing 3 (NLRP3) protein is probably the most 127 studied pattern recognition receptors (PRRs), that assemble inflammasome complex upon 128 activation (1). The full canonical activation of the NLRP3 inflammasome is dependent on a two 129 steps process (2). The first step, named "priming", controls the transcriptional upregulation of 130 NLRP3 and the inflammasome substrates pro-IL-18, pro-IL-18, as well as license NLRP3 for 131 later activation through post-translational modifications including phosphorylations (3,4) and 132 deubiquitinations (5) linked to structural changes and subcellular relocalisation. The second 133 step, named "activation" initiates the final conformation change of NLRP3 protomers. During 134 the priming/activation process NLRP3 transient from an inactive ADP-bound 10-12mers 135 NLRP3 "cage" structure to an active ATP-bound pentamers inflammasome (6-9) leading to 136 137 caspase-1 activation, and therefore the maturation and release of IL-1 $\beta$  and IL-18 as well as pyroptotic inflammatory cell death. Heterozygous missense gain of function variants in NLRP3 138 139 have been associated with an autoinflammatory syndrome called cryopyrin-associated periodic syndrome (CAPS) (10). Besides systemic inflammation, intermittent fever and arthralgia, 140 141 CAPS patients display very specific features including pseudo-urticarial rash often triggered by exposure to cold, neuroinflammatory features such as aseptic meningitidis, sensorineural 142 hearing loss, various ocular manifestations like conjunctivitis and uveitis, and less frequently 143 144 oral aphtous and digestive features(11). Interestingly, NLRP3 pathogenic variants found among CAPS patients are almost exclusively located in the NACHT domain of NLRP3. These 145 mutations are thought to impact ATPase activity or key subdomain interaction surface that 146 intervene in the final opening of the inflammasome structure (8,9) As a result, priming step 147 alone is sufficient to drive significant IL-1β production and this *in vitro* dysregulation profile is 148 therefore considered as a signature of CAPS (12). The most effective treatment for CAPS 149 patients are IL-1 $\beta$  inhibitors (13)(14). 150

- 151
- 152
- 153
- 154
- 155
- 156

Fayand et al 6

#### 157 <u>Methods</u>

#### 158 Human sample collection.

The blood from healthy donors was obtained from "Etablissement Français du Sang" 159 (convention # 07/CABANEL/106), Paris, France. For CAPS patients' blood, the study was 160 approved by the Comité de Protection des Personnes (N° EudraCT: 2018-A01358-47) in 161 France. Experimental procedures with human samples were done according to the European 162 Union guidelines and the Declaration of Helsinki. Clinical data were extracted from the JIR 163 (Juvenile Inflammatory Rheumatism)- cohort; an international multicenter data repository 164 established by the National Commission on Informatics and Liberty (CNIL; authorization 165 number No: 914677). Patients consented to be included in the JIR-cohort and were informed 166 that data collected in medical records might be used for research studies in accordance with 167 privacy rules. 168

169

#### 170 Culture conditions

*In vitro* experiments were performed using frozen human mononuclear cells from peripheral
blood isolated by centrifugation in density gradient medium (STEMCELL Technologies).
Human monocytes were purified by positive selection with Human CD14 microbeads
(Miltenyi). Peripheral blood mononuclear cells (PBMC) and monocytes were cultured in RPMI
1640 (Invitrogen, Gaithersburg, MD) (R10) containing 10% heat-inactivated fetal bovine
serum.

177

#### 178 Measurement of ASC protein aggregates in serum

Sera ASC aggregates were determined using an adaptated previously described method adapted for our purposes (24). One hundred microliters of patients or HC serum were incubated with 2.5  $\mu$ L of phycoerythrin anti-ASC (TMS-1) antibody (Biolegend) for 1 hour at room temperature. Analyses were performed on the BD LSRFortessa<sup>TM</sup> X-20 flow cytometer instrument (BD Biosciences). Nonfluorescent 1- $\mu$ m microspheres (Thermo Fisher Scientific) were used as a guide to gate around ASC specks. Total events in the gated area were divided by 100 for the evaluation of ASC speck per microliter.

#### 187 IL-1β and IL-18 detection by ELISA

PBMCs were seeded at  $1.10^6$  cells /mL and monocytes isolated from PBMCs at  $1.10^5$  cells /mL. 188 Standard protocol consists in a priming with LPS 10ng/ml. After 3h PBMC were activated with 189 MSU (monosodium urate crystals) 200µg/ml. After 3 hours the media were collected and 190 analyzed by ELISA. For kinetic experiments, the media were collected 30 minutes, 1 hour, 2 191 hours, 3 hours and 6 hours after MSU. For basal production on unstimulated cells, PBMC or 192 purified monocytes were cultured overnight. IL-1β and IL18 were measured in cell supernatant 193 and/or patient's plasma using a kit from R&D (DY201-05 and DY318-05 respectively) 194 195 according to supplier recommendations.

196

#### 197 Legendplex:

198 Cytokines in patients' plasma were quantified using bead-based multiplex assays 199 (LEGENDplex 13-plex HU Essential Immune Response Panel). The experiment was conducted 200 according to the manufacturer protocol. Briefly, diluted plasma were incubated with Capture 201 Beads for 2h. Following centrifugation, supernatants were discarded and biotinylated detection 202 antibodies were added for 1h. After incubation with SA-PE, supernatants are discarded and 203 samples are resuspended in the provided wash buffer to read on the flow cytometer.

204

#### 205 In silico Modeling:

All in silico studies were performed within the Biovia Discovery Studio (DS 2022) suite. 206 207 Mutants models were generated using the cryo-EM structure of the wt NLRP3 in complex with NEK7 (PDB: 6NPY) and the Modeller program (Version: 9.24) implemented in the Building 208 209 Mutant protocol of DS. Short Molecular Dynamics MD simulations (5 ns) were run using the NAMD program (25) implemented in DS and the CHARMM36m force field. The average 210 interfacial interaction energy between NLRP3 and NEK7, based on the sum of the van der 211 Waals and electrostatic interactions was calculated on the last ns of the 5ns MD simulations 212 using the Calculate Interaction Energy tool of DS- Analysis of the NLRP3/NEK7 interactions 213 was conducted with the Analysis Protein Interface tool. 214

215

216 Statistics

All statistical analyses were performed using GraphPad Prism (version 9.1.1). Data on the figures are presented as mean (± SD for the kinetic experiments). For experimental data, statistical analysis were performed either using non-parametric One-way ANOVA followed by Kruskal-Wallis multiple comparison test or non-parametric 2-tailed Mann-Whitney test (IL-18 plasma assay). For clinical information, non-categorical data were analyzed using Mann Whitney test and categorical data using Fisher test. P values less than 0.05 were considered significant.

224

#### 225 <u>Results</u>

#### 226 Pathogenic variants of the residue 861 in NLRP3 drive an atypical CAPS disease.

227 Nine patients carrying a heterozygous Y861C missense variant (NM\_004895.5 : c.2582A>G

p.(Tyr861Cys)) of NLRP3, and 5 carrying a heterozygous Y861H variant (NM\_004895.5 :

c.2581T>C p.(Tyr861His)) were included in France, Holland, and Portugal (15,16). Depending
on the first methionine used for numbering, these variants are also known as c.2576A>G
p.(Tyr859Cys) and c.2575T>C p.(Tyr859His) using NM\_001243133.2. These variants are

respectively reported pathogenic and likely pathogenic in the ClinVar database.

Unlike most CAPS causing pathogenic variants that are located in the NACHT domain, these
substitutions involve a tyrosine residue in the LRR domain of NLRP3 (Figure1A). All patients
belonged to large families with dominant transmission of the mutation (Figure 2).

While these patients display typical features of CAPS as ophthalmological manifestations such 236 237 as recurrent conjunctivitis, uveitis or papillary edema (93%), arthromyalgia (79%) and aseptic meningitidis (43%) (Figure 1 B, C, D and E), some other main features are significantly 238 239 differentially observed compared to our cohort of 48 CAPS patients with pathogenic variants outside of the LRR domain. Indeed, they have more sensorineural hearing loss (100% Vs 63%, 240 p=0.006), more headaches (86% Vs 45%, p=0.013), less urticarial rash (29% Vs 94%, p<0.001) 241 and less aphtosis (7% Vs 53%, p=0.004). Of note, 3 patients from a same family had 242 hypereosinophilia, a feature not found in our typical CAPS cohort (21% Vs 0%, p=0.037) (table 243

**I and sup table I**.

In order to confirm that the patients with substitution of the tyrosine residue at position 861 of

246 NLRP3 were affected by an inflammasomopathy we quantified ASC speck and IL-18 in their

plasma. ASC speck concentration in plasma of NLRP3<sup>Y861C</sup> patients was higher than in healthy

248 donors and comparable to the levels observed in typical CAPS patients or patients with FMF

(Figure 1 F). Similarly, IL-18 concentration was significantly higher in NLRP3<sup>Y861C</sup> patients compared to controls (mean: 216,4 pg/ml  $\pm$  9,1 pg/ml and 84,1 pg/ml  $\pm$  4,1 pg/ml respectively; p=0,0023 – Two-tail Mann-Whitney test) (Figure 1 G). No other cytokine were found to be significantly over express in typical CAPS or NLRP3<sup>Y861C</sup> patients (Sup Fig1).

Finally, in line with these results and what is known in classical CAPS, IL-1β inhibitors were
very efficient in all patients. Most clinical symptoms quickly resolved, with marked
improvement in general condition and almost complete resolution of headache, ophthalmic
manifestations and arthralgia. Additionally, hearing ceased to deteriorate. Accordingly,
biological response was immediate, with normalization of CRP, SAA and blood count within
8 days.

259

# Activation signal is required to fully activate inflammasome in cells from NLRP3<sup>Y861C</sup> patients.

To date, the only characterisation of primary immune cells from NLRP3<sup>Y861C</sup> mutated patients 262 suggests that patients' PBMCs spontaneously produced IL-1 $\beta$ , in the absence of any stimulus, 263 either prime and/or boost signal (15). However, in our hands, neither PBMC nor isolated 264 monocytes from NLRP3<sup>Y861C</sup> produced IL-1 $\beta$  in the absence of a priming or activating signal 265 (Figure 3A and B). Thus, we tested the response of NLRP3<sup>Y861C</sup> mutated cells to priming signal 266 only. As for cells from healthy donors, priming with LPS alone induced a very slight production 267 of IL1-B in NLRP3<sup>Y861C</sup> mutated PBMCs and monocytes while NLRP3 NACHT domain 268 mutated cells were producing higher quantities (2,4  $\pm$  0,48 fold HD, p >0.999 and 21,7  $\pm$  0,99 269 fold HD, p = 0,0050 respectively for PBMC, One-way ANOVA, Kruskal-Wallis test) (Figure 270 **3C** and **D**). These results strongly suggest that NLRP3<sup>Y861C</sup> patients have a distinct 271 272 pathophysiological mechanism compared to the more common CAPS driving NACHT pathogenic variants of NLRP3. Finally, the comparison of IL1<sup>β</sup> production after prime plus 273 boost stimulation in cells from healthy donors, NLRP3<sup>Y861C</sup> mutated patients and typical CAPS 274 patients returned comparable levels (Figure 3C and D). Overall, despite compelling clinical 275 and genetic evidence that NLRP3<sup>Y861C</sup> drives an atypical CAPS phenotype in most patients, our 276 in vitro results could not differentiate NLRP3 activation between healthy donors and 277 NLRP3<sup>Y861C</sup> mutated patients. 278

## Cells from NLRP3<sup>Y861C</sup> patients demonstrate sustained IL-1β production compared to cells from healthy donors.

Recently, *Caseley et al* reported a patient with a NLRP3<sup>R920D</sup> substitution in the LRR domain of NLRP3 resulting in an atypical inflammatory syndrome (17). Based on modelling studies, the authors suggested that the mutation enhanced the electrostatic complementarity between the LRR portion of NLRP3 and NEK7 leading to an increased binding affinity between the two partners. Since Y861 is located at the interface of NLRP3 and NEK7 (**Figure 4A**), we hypothesized that Y861 pathogenic variants might potentially enhance the NLRP3/NEK7 binding as well.

To evaluate the impact of the Y861C and Y861H substitution on the stability of the interaction 289 290 between NLRP3 and NEK7, we performed short Molecular Dynamics (MD) simulations starting from the cryoEM structure of the NLRP3/NEK7 complex (PDB:6NPY, (18)). We 291 examined the binding interface of C861 and H861 mutant models and calculated the interaction 292 energy for each NLRP3/NEK7 complex. A model of the R920Q mutation was also generated 293 for the sake of comparison. Our results with R920Q model are in agreement with those 294 previously reported by Caseley et al (17). R920Q mutation resulted in an enhanced binding 295 between NLPR3 and NEK7 (Figure 4A). Compared to WT, Y861C model had a positive effect 296 on stability between NLRP3 and NEK however the Y861H mutation proved to be detrimental 297 to the stability of the NLRP3/NEK interface. Thus, given the phenotypic similarities between 298 299 Y861C and Y861H patients, increased binding affinity between NLRP3 and NEK7 probably does not explain the atypical phenotypes observed in most of these patients. This might also be 300 supported by the strong phenotypic difference between the NLRP3 R920Q mutated patient and 301 NLRP3 Y861C, and Y861H patients. 302

303 Previous work in mice and human derived monocytic cell lines (19) suggest that the Y861 residue (Y859 in mice) is central for the control of NLRP3 activation. It is proposed that 304 305 phosphorylation of Y861 promotes the addressing of activated NLRP3 to phagolysosome leading to a reduction of the NLRP3 pool available for inflammasome assembly (20). We 306 anticipate that such mechanism should results in increased early production of IL-1ß by 307 patient's cells. In order to test this hypothesis, we performed a kinetic of IL-1ß production 308 following LPS and MSU stimulation on isolated monocytes from healthy donors and 3 309 NLRP3<sup>T861C</sup> mutated patients. Our results highlight a strongest production of IL1 $\beta$  during the 310 first two hours post boost in monocytes from the 3 NLRP3<sup>T861C</sup> mutated patients compared to 311 healthy donors supporting our hypothesis (Figure 4B). We also observed a sustained 312

Fayand et al 11

314 production of IL1 $\beta$  in monocytes from patients. Indeed, while the secretion stopped after 3

hours in cells from most healthy donors, we could still observe a production of IL-1 $\beta$  between

316 3 and 6 hours post boost in the monocytes from the 3 tested NLRP3<sup>T861C</sup> mutated individuals

317 (Figure 4C). These latest results also support the hypothesis of a defective deactivation of the

318 inflammasome complex.

#### 319 **Discussion**

Altogether, we describe 14 patients with pathogenic variants located in the LRR domain of 320 321 NLRP3 at position 861. This series highlights a clear genotypes /phenotypes correlation with all patients displaying hearing loss, and 10 out of 14 devoid of pseudo-urticarial rash (Figure 322 5). This remarkable difference in phenotype observed in patients with pathogenic variants 323 outside the LRR domain (21) might be explained by the distinct activation profile of NLRP3 324 depending on the localization of the disease-causing variants. Indeed, in contrast to cells from 325 typical CAPS, PBMCs and monocytes from NLRP3<sup>T861C</sup> mutated patients required a boost 326 signal for full inflammasome activation. However, patients' cells demonstrated exacerbated 327 early IL1ß secretion and sustained IL1ß secretion following "prime and boost" activation when 328 compared to healthy donors. It remains unclear what causes this exacerbated response to 329 stimuli. Previous studies in mice suggest that phosphorylation of the Y859 residue promote 330 NLRP3 degradation (19). In their models, defective phosphorylation of Y859 is associated with 331 defective addressing of activated NLRP3 to phagolysosomes (20). Nevertheless, another study 332 performed using human NLRP3 expressed in mice cells suggests that it is not the 333 phosphorylation of Y861, but the phosphorylation of Y918 that control NLRP3 activity (22). 334 Further experiments will be needed on human cells to confirm or exclude the contribution of 335 Y861 to NLRP3 degradation. Another nonexclusive hypothesis is that the modification of the 336 electrostatic charge of NLRP3 LRR domain caused by the Y861C substitution either stabilizes 337 the active inflammasome complex or destabilizes the inactive cage conformation. Indeed, 338 charges in the LRR concave side plays a major role in NEK7 recruitment to NLRP3 to form the 339 inflammasome and Y861C may drives an increase affinity of NLRP3 for NEK7, thus resulting 340 in an overactivated inflammasome. A similar mechanism was already reported for a R920Q 341 substitution causing an atypical auto inflammatory disease (17). Further experimental 342 approaches are needed to fully understand how these mutation impact NLRP3 function and 343 regulation and contribute to the CAPS phenotypes. Of note, we observed a non-statistically 344 significant trend towards an overall increase IL-1ß secretion in cells from Y861C patients 345

compare to cells from healthy donors upon LPS + MSU treatment. Future experiment on a
larger group of patients and control should help to determine if this observation is due to interindividual variability or is a hallmark of this mutation.

The low prevalence of skin manifestation and aphtosis associated to the high prevalence of 349 deafness and headaches in NLRP3<sup>Y861C</sup> and NLRP3<sup>Y861H</sup> mutated patients might be explained 350 by the distinct pathophysiological mechanism compared to typical CAPS. Skin pseudo-351 352 urticarial rash seen in most CAPS could result from a local production of IL-1<sup>β</sup> triggered by an uncontrolled priming signal in patients with mutation leading to activation signal independent 353 354 NLRP3 inflammasome formation (ie mutation in the NACHT domain). Conversely, the preserved dependence on the boost of Y861 pathogenic variants could protect these patients 355 from the cutaneous phenotype of CAPS. On the other hand, NLRP3<sup>Y861C</sup> and NLRP3<sup>Y861H</sup> 356

357

mutated patients show high prevalence of sensorineural hearing loss which is reminiscent of what was observed in two families with a NLRP3 <sup>R920D</sup> mutation which is in the close vicinity of Y861 (23). Better understanding of the impact of these variants on local and systemic inflammation in humans might help to explain these phenotypic specificities.

362

In conclusion, it appears that the differential diagnosis of a dominantly inherited sensorial hearing loss should include cryopyrinopathy in individuals with elevated CRP, even in the absence of urticaria. This is particularly true in patients with ophthalmological (conjunctivitis) and neurological (headache) features and hypereosinophilia. A genetic sequencing looking for *NLRP3* pathogenic variants by next generation sequencing could reduce the diagnostic delay and prevent the risks of hearing or visual sequelae and AA amyloidosis.

369

#### 370 Acknowledgments

We thank all the affected patients and their family, and the healthy individuals used as controls. We thank the Macromolecular Modeling Platform of UMR8601, Université de Paris Cité for it help with modelling, Agence Régionale de Santé Île-de-France and hôpitaux universitaires de Strasbourg for supporting the project with the "bourse année-recherche" educational grant and "la Foundation pour la Recherche Médicale" for providing the Ph.D scholarship of Margaux Cescato. We thank Irina Giurgea for her help with several French patients genotyping. 377

#### 378 Funders

- 379 SGL: ANR INFLAMAST AAPG 2017 CE17 and foundation APHP.
- 380 MPR was supported by the Agence National de la Recherche: ANR-21-CE17-0025 JDMINF2.

- 382 Data Availability
- 383 The datasets generated during and/or analysed during the current study are available from the
- 384 corresponding author on reasonable request.

#### **Bibliography** 385 Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and 386 1. regulation to therapeutics. Nat Rev Immunol. 2019 Aug;19(8):477-489. 387 388 2. He Y, Hara H, Núñez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016 Dec;41(12):1012–1021. 389 3. Song N, Liu Z-S, Xue W, Bai Z-F, Wang Q-Y, Dai J, et al. NLRP3 phosphorylation is an 390 391 essential priming event for inflammasome activation. Mol Cell. 2017 Oct 5;68(1):185-197.e6. 392 393 4. Niu T, De Rosny C, Chautard S, Rey A, Patoli D, Groslambert M, et al. NLRP3 394 phosphorylation in its LRR domain critically regulates inflammasome assembly. Nat Commun. 2021 Oct 6;12(1):5862. 395 396 5. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-397 transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem. 2012 Oct 19;287(43):36617–36622. 398 399 6. Fletcher DJ. Coping with insomnia. Helping patients manage sleeplessness without drugs. 400 Postgrad Med. 1986 Feb 1;79(2):265-274. Andreeva L, David L, Rawson S, Shen C, Pasricha T, Pelegrin P, et al. NLRP3 cages 401 7. 402 revealed by full-length mouse NLRP3 structure control pathway activation. Cell. 2021 Dec 403 22;184(26):6299-6312.e22. 404 8. Brinkschulte R, Fußhöller DM, Hoss F, Rodríguez-Alcázar JF, Lauterbach MA, Kolbe C-C, et al. ATP-binding and hydrolysis of human NLRP3. Commun Biol. 2022 Nov 405 3;5(1):1176. 406 407 9. Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome 408 disc. Nature. 2022 Nov 28; 409 10. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory 410 syndrome and Muckle-Wells syndrome. Nat Genet. 2001 Nov;29(3):301-305. 411 Quartier P, Rodrigues F, Georgin-Lavialle S. [Cryopyrin-associated periodic syndromes]. 412 11. Rev Med Interne. 2018 Apr;39(4):287-296. 413 414 12. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms 415 an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004 Mar;20(3):319-325. 416 Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in 417 13. Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004 Feb;50(2):607-418 419 612. 420 14. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by 421 interleukin-1 receptor antagonist. Lancet. 2004 Nov 19;364(9447):1779-1785. 422 423 15. Jéru I, Marlin S, Le Borgne G, Cochet E, Normand S, Duquesnoy P, et al. Functional 424 consequences of a germline mutation in the leucine-rich repeat domain of NLRP3 425 identified in an atypical autoinflammatory disorder. Arthritis Rheum. 2010

426 Apr;62(4):1176–1185.

- 427 16. Mulders-Manders CM, Kanters TA, van Daele PLA, Hoppenreijs E, Legger GE, van Laar
  428 JAM, et al. Decreased quality of life and societal impact of cryopyrin-associated periodic
  429 syndrome treated with canakinumab: a questionnaire based cohort study. Orphanet J
  430 Rare Dis. 2018 Apr 20;13(1):59.
- 431 17. Caseley EA, Lara-Reyna S, Poulter JA, Topping J, Carter C, Nadat F, et al. An atypical
  432 autoinflammatory disease due to an LRR domain NLRP3 mutation enhancing binding to
  433 NEK7. J Clin Immunol. 2022 Jan;42(1):158–170.
- 434 18. Sharif H, Wang L, Wang WL, Magupalli VG, Andreeva L, Qiao Q, et al. Structural
  435 mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature. 2019 Jun
  436 12;570(7761):338–343.
- 437 19. Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, et al. NLRP3 tyrosine
  438 phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J Clin Invest.
  439 2016 May 2;126(5):1783–1800.
- Spalinger MR, Lang S, Gottier C, Dai X, Rawlings DJ, Chan AC, et al. PTPN22 regulates
  NLRP3-mediated IL1B secretion in an autophagy-dependent manner. Autophagy. 2017
  Sep 2;13(9):1590–1601.
- Levy R, Gérard L, Kuemmerle-Deschner J, Lachmann HJ, Koné-Paut I, Cantarini L, et
  al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a
  series of 136 patients from the Eurofever Registry. Ann Rheum Dis. 2015
  Nov;74(11):2043–2049.
- Tang J, Xiao Y, Lin G, Guo H, Deng H-X, Tu S, et al. Tyrosine phosphorylation of NLRP3
  by the Src family kinase Lyn suppresses the activity of the NLRP3 inflammasome. Sci
  Signal. 2021 Oct 26;14(706):eabe3410.
- Asamishi H, Kawashima Y, Kurima K, Chae JJ, Ross AM, Pinto-Patarroyo G, et al.
  NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy. Proc Natl Acad Sci USA. 2017 Sep 12;114(37):E7766–E7775.
- 454 24. Rowczenio DM, Pathak S, Arostegui JI, Mensa-Vilaro A, Omoyinmi E, Brogan P, et al.
  455 Molecular genetic investigation, clinical features, and response to treatment in 21 patients
  456 with Schnitzler syndrome. Blood. 2018 Mar 1;131(9):974–981.
- 457 25. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable
  458 molecular dynamics with NAMD. J Comput Chem. 2005 Dec;26(16):1781–1802.
- 459
- 460

#### **Tables**

462 Table I : Clinical features of CAPS patients associated with non LRR pathogenic variants and bearing Y861H or
 463 Y861C variants

General features	Non LRR mutated CAPS (n = 48)	LRR mutated CAPS (n = 14)	P-value
Mean age at symptoms onset and range (years old)	4,5 (0-46)	10,1 (3-32)	<0,0001
Mean age at diagnosis and range (years old)	33,7 (0-73)	32,6 (7-54)	0,9015
Mean diagnostic delay and range (years)	29,2 (0-73) 22,4 (4-39)		0,3842
Familial form	35/48 (73%)	14/14 (100%)	0,0290
Mosaicism	4/48 (8%)	0/14 (0%)	0,5659
linical features			
Sensorineural hearing loss	29/46 (63%)	14/14 (100%)	0,0060
Urticarial rash	45/48 (94%)	4/14 (29%)	<0,000
Aphtosis	23/43 (53%)	1/14 (7%)	0,0039
Hypereosinophilia before treatment	0/26 (0%)	3/14 (21%)	0,0368
Headache	21/46 (45%)	12/14 (86%)	0,0128
Meningitis and/or intracerebral hypertension	12/46 (26%) 6/14 (43%)		0,3188
Intellectual impairment	4/47 (9%)	0/14 (0%)	0,5650
Arthromyalgia	42/46 (91%)	11/14 (79%)	0,3375
Conjunctivitis	29/47 (62%)	11/14 (79%)	0,3421
Uveitis and/or papillary edema	18/46 (39%)	7/14 (50%)	0,5434
IBD-like symptoms	4/45 (9%)	1/12 (8%)	>0,999
Other digestive involvement (abdominal pain, nausea, hepatosplenomegaly)	4/21 (19%)	4/10 (40%)	0,3809
Presence of amyloidosis AA	3/47 (6%)	0/14 (0%)	>0,999
Mean age at amyloidosis diagnosis and range (years old)	26 (14-38)	/	
reatment			
Mean age at start of treatment and range (years old)	35,4 (4-74)	34,5 (14-54)	0,9739
Use of anakinra	20/25 (80%)	7/11 (63%)	0,4088
Use of canakinumab	33/33 (100%)	10/10 (100%)	>0,999
Good response to treatment	41/45 (91%)	14/14 (100%)	0,5635

*bowel disease* 

#### 468 Figure 1: Mutations of residue 861 of NLRP3 drive an inflamasommopathy.

A) Representation of NLRP3 with known mutated amino acid in CAPS patients highlighted in red and the Y861 in light blue. **B)** Picture of P6 left eye showing conjunctivitis **C)** Fundus color photograph of

471 patient P1 right eye showing an optic disc atrophy. **D**) Finger of P1 showing digital clubbing fingers. **E**)

472 Audiograms of P1. F) Quantification of ASC speck in the plasma of healthy donors, typical CAPS

- 473 patients, NLRP3 Y861C patients and FMF patients. G) Quantification of IL-18 in the plasma of healthy
- donors and NLRP3 Y861C patients
- 475
- 476 **Figure 2:** Pedigrees of 4 families with NLRP3 Y861C and Y861H pathogenic variants.
- 477

#### 478 Figure 3: Cells from patients with Y861C substitution required a boost signal to be activated.

- 479 A) Quantification of basal production of IL1 $\beta$  during overnight culture from PBMC or B) monocytes of
- 480 healthy donors, typical CAPS patients and NLRP3 Y861C patients. C) quantification of IL1β production
- 481 of PBMC or D) monocytes of healthy donors, typical CAPS patients and NLRP3 Y861C patients
- 482 following LPS and LPS + MSU stimulation (3 hours priming + 3 hours activating signal)
- 483

#### 484 Figure 4: Cells from patients with Y861C substitution demonstrate sustained IL-1β production.


A) Up: Structure of the NLRP3 (yellow)/NEK7 (red) interface (PDB: 6NPY) near the residue Y861
(cyan). Basic residues of NEK7 (ie K128, K130, R131) are involved in electrostatic interactions (dashed
bond) with W776, E802 and E864 of NLRP3. Down: Predicted impact of selected mutation on
NEK7/NLRP3 interactions through MD simulations. The table display the key interface residues
involved in electrostatic interactions and energies calculations. The interfacial interaction energy is
considered in van der Waals and electrostatic terms. B) As for the previously describe R920Q mutation,


491 Y861C is predicted to stabilize NLRP3/NEK7 interaction compared to WT. However, Y861H is

- 492 predicted to be detrimental **B**) Quantification of IL1 $\beta$  production over time of monocytes from healthy 493 donors and 3 NLRP3 Y861C patients. **C**) Quantification of the production of IL1 $\beta$  between 3 hours and
- 495 donors and 5 NLKP5 1 801C patients. C) Quantification of the production of 1L1p betwee
- 6 hours post boost in monocytes healthy donors and NLRP3 Y861C patients.
- 495


496 Figure 5: Graphical abstract. CAPS patients with pathogenic variant at position 861of NLRP3 are
497 more susceptible to headache and hearing loss than patients with variants in the NACHT domain.
498 Inversely, NACHT mutated patients are more susceptible to aphtosis and urticarial rash.


### Figure 1
















Figure 2






CAPS A439V H360R T348M



PBMC




A


400


300


Α



NLRP3 Genotypes	Interacting AA from NLRP3	Interacting AA from NEK7	Interaction energy (kcal/mol)	Electrostatic energy (kcal/mol)	Van der Waals energy (kcal/mol)
Y861 (WT)	D750, D804, D807, E864	R121, K128, R131, K140	-383.0	-326.9	-56.1
C861	E356, K696, D747, D750	R131, K140, D261, R294	-501.9	-424.2	-77.7
H861	K696, D750, E864	K128, K140, D261	-351.2	-310.1	-41.1
Q920	K696, D750, D804, E864, E1007, E1033,	K124, K127, K128, R131, K140, D261	-451.8	-413.0	-38.8







Sup fig 1: Screening of the plasmatique levels of 10 inflammatory cytokines did not reveals any significant difference between typical CAPS and NLRP3 Y861C patients.